Aptose Biosciences Inc.
aptose.comWhat Do They Do?
Develops oral targeted cancer drug candidates for blood cancers, including tuspetinib for acute myeloid leukemia and higher-risk myelodysplastic syndromes.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
-
Jul 1, 2026
Hanmi completed its acquisition of Aptose
Aptose became a wholly owned subsidiary of the Hanmi Purchasers.
Sources
8-K, filed Jul 1, 2026
Pursuant to the Arrangement Agreement, dated as of November 18, 2025, as amended and restated by the parties on February 23, 2026 (the…View ↗
Active pipeline
The older report described tuspetinib and luxeptinib as under active development; the latest identifies tuspetinib as active and says luxeptinib is not undergoing active clinical development.
10-K for FY2022, filed Mar 24, 2023 10-K for FY2025, filed Mar 31, 2026Aptose is advancing oral targeted agents to treat life-threatening cancers that, in most cases, are not elective for patients and require…View ↗
We are advancing oral targeted agents to treat life-threatening hematologic cancers that require immediate treatment. We have one…View ↗
Loading...
